---
category: news
title: "Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy"
excerpt: "Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology,"
publishedDateTime: 2022-10-06T12:08:00Z
originalUrl: "https://www.joplinglobe.com/region/national_business/kiromic-biopharma-announces-fda-feedback-from-type-b-pre-ind-meeting-confirms-deltacel-development-strategy/article_3ebcfa93-c18c-5cfe-bab8-ad1677e4298c.html"
webUrl: "https://www.joplinglobe.com/region/national_business/kiromic-biopharma-announces-fda-feedback-from-type-b-pre-ind-meeting-confirms-deltacel-development-strategy/article_3ebcfa93-c18c-5cfe-bab8-ad1677e4298c.html"
type: article
quality: 6
heat: 6
published: false

provider:
  name: Joplin Globe
  domain: joplinglobe.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "http://static.cnhionline.com/joplinglobe/jmag/Jmag-Oct22Cvr.jpg"
    width: 350
    height: 456
    isCached: true

secured: "ZQ9n1pJFMxQO9GTMp43JqMXRKlhjmPKOOnG5yzggau/vQTTgWmwibjvDsOnts0U4Q/fkCPam1TvcazbdHk2YXlhTGk48EV7VUXj9saRd/TF/5wXX7AOcZ1G/UEUSuDSHPUszuBqMy/B0UwqSlVneeoLAIZClv2PIVL6O0hu4ZN3TCqq/hPiB6mLbkvZFFjy9q+GktcL524fgDKkRUqmOyzoPEqNP6IM01JdISfg5TszEB21leclLxnBY43Hy9oA4Vg7vh/a/ghUbBV6OcGhNZd3WJwx0Bi72Sp0DautoKbXiUVvOoMi6tgQPbVoG6xG3lCiZW1tEmoO2th2Tyiz9wvwoy4/uo87UdF/9W4LFB40=;EmDcjahBxV5KOqWUvoimBw=="
---

